adelmidrol
Description
adelmidrol: Antiinflammatory Agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 176874 |
| CHEMBL ID | 2105967 |
| SCHEMBL ID | 636771 |
| MeSH ID | M0550492 |
Synonyms (31)
| Synonym |
|---|
| nsc-27132 |
| nsc27132 |
| 1675-66-7 |
| adelmidrol |
| n,n'-bis(2-hydroxyethyl)nonanediamide |
| nsc 27132 |
| unii-1buc3685qu |
| adelmidrol [inn] |
| CHEMBL2105967 |
| 1buc3685qu , |
| S6551 |
| adelmidrol [who-dd] |
| CCG-213729 |
| SCHEMBL636771 |
| CS-4543 |
| nonanediamide, n,n'-bis(2-hydroxyethyl)- |
| HY-B1026 |
| AB01563184_01 |
| DTXSID10168302 |
| AKOS028111150 |
| EX-A1239 |
| SR-01000944279-1 |
| sr-01000944279 |
| BCP24910 |
| Q15633949 |
| n1,n9-bis(2-hydroxyethyl)nonanediamide |
| FT-0778179 |
| C73226 |
| AS-56183 |
| adelmitrol |
| BAA67566 |
Research Excerpts
Overview
Adelmidrol is a semisynthetic derivative of azelaic acid. It is an analogue of the anti-inflammatory compound palmitoylethanolamide (PEA)
| Excerpt | Reference | Relevance |
|---|---|---|
| "Adelmidrol is a semisynthetic derivative of azelaic acid and analogue of the anti-inflammatory compound palmitoylethanolamide (PEA). " | ( Inhibitory effect of topical adelmidrol on antigen-induced skin wheal and mast cell behavior in a canine model of allergic dermatitis. Brazis, P; Cerrato, S; Della Valle, MF; Miolo, A; Puigdemont, A, 2012) | 2.11 |
Treatment
Adelmidrol treatment, moreover, reduced nuclear factor-κB translocation, cyclooxygenase-2, and phosphoextracellular signal-regulated kinase expression; proinflammatory cytokine release.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Adelmidrol treatment, moreover, reduced nuclear factor-κB translocation, cyclooxygenase-2, and phosphoextracellular signal-regulated kinase expression; proinflammatory cytokine release; and the incidence of nitrotyrosine and poly(ADP)ribose in the colon." | ( Adelmidrol, a Palmitoylethanolamide Analogue, as a New Pharmacological Treatment for the Management of Inflammatory Bowel Disease. Cordaro, M; Crupi, R; Cuzzocrea, S; Esposito, E; Gugliandolo, E; Impellizzeri, D; Siracusa, R, 2016) | 2.6 |
| "Treatment with adelmidrol decreased diarrhea, body weight loss, and myeloperoxidase activity." | ( Adelmidrol, a Palmitoylethanolamide Analogue, as a New Pharmacological Treatment for the Management of Inflammatory Bowel Disease. Cordaro, M; Crupi, R; Cuzzocrea, S; Esposito, E; Gugliandolo, E; Impellizzeri, D; Siracusa, R, 2016) | 2.22 |
Compound-Compound Interactions
The aim of this study was to evaluate the effect of adelmidrol, a synthetic palmitoylethanolamide analogue, combined with hyaluronic acid on pain severity and modulation of the inflammatory response in a rat model of monosodium iodoacetate-induced osteoarthritis.
Research
Studies (14)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 4 (28.57) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 40.66
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (40.66) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (7.14%) | 5.53% |
| Reviews | 1 (7.14%) | 6.00% |
| Case Studies | 1 (7.14%) | 4.05% |
| Observational | 1 (7.14%) | 0.25% |
| Other | 10 (71.43%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||